65,437 trials
Hypertriglyceridemia · Atherosclerotic Cardiovascular Disease · Severe Hypertriglyceridemia
Primary: Percent Change From Baseline in Fasting TG at Month 6 — -7.77; -57.05; -60.92 Percent Change — p=<0.0001
Asthma · Depression · Childhood Asthma
Primary: FEV1 Percent Change Post-ipratropium — 10.8 percent change — p=0.032
Hernia · Ventral Hernia · Incisional Hernia
Primary: Number of Participants With Early Postoperative Safety Events (Surgical Site Infection, Mesh-Related Adverse Events, or Reoperation) — 4; 0; 0; 0 Participants
Solid Tumors · Lymphomas
Primary: Number of Subjects With Treatment Emergent Adverse Events (TEAE) — 3; 3; 3; 3 participants
Retinitis Pigmentosa
Primary: Number of Subjects With Serious Adverse Events — 0; 0 Participants
Multiple Myeloma
Primary: Percentage of Participants Who Achieved a Complete Response (CR) by International Myeloma Working Group (IMWG) Criteria — 4.9; 12.2; 0 percentage of participants
Cigarette Smoker · Current Every Day Smoker
Primary: Changes in Cytokines — 0.2473; -0.04988; -0.1137; -0.05875 pg/ml
Thoracic Tumours
Primary: Toxicity Rate of Dose Limiting Toxicities (DLTs) Assessed by CTCAEv4 — 0; 0; 0; 0 Participants
Treatment-resistant Depression
Primary: Number of Participants Without Serious Adverse Events During Propofol Infusions — 16 Participants
Borderline Personality Disorder
Primary: Zanarini Rating Scale for Borderline Personality Disorder (ZAN-BPD) — 8.74; 5.80 Score on a scale
Kidney Transplant Recipients · Liver Transplant Recipients
Primary: The -Fold Change in Antibody Titer (Using the Roche Elecsys® Anti-SARS-CoV-2 S Assay) From Before Receiving the Study Dose of Vaccine to 30 Days After the Study Dose of…
Analgesia · Anesthesia
Primary: CSF Flow Measured in Hz — -15 Hz
Contraception Behavior
Primary: Number of Participants With Implant Continuation — 219; 225 Participants
Healthy Volunteers · Alcohol Drinking Related Problems · Alcohol-Related Disorders
Primary: Alcohol Attention Bias Signal - Stage 1 — 0.007121461; 0.135970228; -0.015216812; 0.112620872 Arbitrary units (A.U)
Pancreatic Ductal Adenocarcinoma
Primary: 12- Month Overall Survival (OS) — 16 Participants